Inventiva Gestion

Gestion contrôle des critères 2/4

Le PDG Inventiva est Frederic Cren, nommé en Jan2011, a un mandat de 13.83 ans. La rémunération annuelle totale est € 1.00M, composée du salaire de 30.4% et des bonus 69.6%, y compris les actions et options de la société. détient directement 6.45% des actions de la société, d'une valeur de € 13.81M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.2 ans et 7.8 ans.

Informations clés

Frederic Cren

Directeur général

€1.0m

Rémunération totale

Pourcentage du salaire du PDG	30.4%
Durée du mandat du directeur général	13.8yrs
Propriété du PDG	6.4%
Durée moyenne d'occupation des postes de direction	8.2yrs
Durée moyenne du mandat des membres du conseil d'administration	7.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Frederic Cren a-t-elle évolué par rapport aux bénéfices de Inventiva?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

Rémunération vs marché: La rémunération totale de Frederic ($USD 1.06M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 793.15K ).

Rémunération et revenus: La rémunération de Frederic a augmenté alors que l'entreprise n'est pas rentable.

PDG

Frederic Cren (58 yo)

13.8yrs

Titularisation

€1,003,699

Compensation

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.6m
Jean Volatier	Deputy GM & CFO	12.3yrs	pas de données	0.17% € 368.5k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	pas de données	0.017% € 36.9k
Eric Duranson	General Counsel	3.3yrs	pas de données	0.017% € 36.9k
Nathalie Harroy	Head of Human Resources	12.8yrs	pas de données	0.075% € 161.6k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	pas de données	pas de données
Michael Cooreman	Chief Medical Officer	4.1yrs	pas de données	0.017% € 36.9k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	pas de données	0.0086% € 18.4k

8.2yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 6IV est chevronnée et expérimentée (8.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.6m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	pas de données
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	pas de données
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	pas de données
Sven Francque	Member of Scientific Advisory Board	no data	pas de données	pas de données
Manal Abdelmalek	Member of Scientific Advisory Board	no data	pas de données	pas de données
Kenneth Cusi	Member of Scientific Advisory Board	no data	pas de données	pas de données
Glen Clack	Member of Scientific Advisory Board	no data	pas de données	pas de données
Gérard Zalcman	Scientific Advisory Board Member	no data	pas de données	pas de données

7.8yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 6IV sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).

Inventiva Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Full year 2023 earnings released: €2.44 loss per share (vs €1.31 loss in FY 2022)

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

First half 2023 earnings released: €1.32 loss per share (vs €0.72 loss in 1H 2022)

New major risk - Negative shareholders equity

New major risk - Financial position

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Full year 2022 earnings released: €1.31 loss per share (vs €1.27 loss in FY 2021)

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

First half 2022 earnings released: €0.72 loss per share (vs €0.60 loss in 1H 2021)

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Full year 2020 earnings released: €0.99 loss per share (vs €1.29 loss in FY 2019)

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

New 90-day high: €12.92

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

New 90-day high: €11.34

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

First half earnings released

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen